Who Paid My Doc
Daniel Arzola Castaner
Clinical Cardiac Electrophysiology Bayamon, PR Medical Doctor
NPI 1548278187 CMS profile 69386
Metromedical # A, Suite 501995 Carr 2, Bayamon, PR 00959
General payments
$15,421
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Daniel Arzola Castaner of Bayamon, PR is reported in the CMS Open Payments database as having received $15,421 across 350 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 45th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,401 | 53 | |
| 2024 | General | $3,291 | 77 | |
| 2023 | General | $1,744 | 61 | |
| 2022 | General | $1,203 | 46 | |
| 2021 | General | $1,025 | 36 | |
| 2020 | General | $1,454 | 21 | |
| 2019 | General | $5,302 | 56 |
Beside peers
- Daniel Arzola Castaner
- Clinical Cardiac Electrophysiology median
- Middle half of Clinical Cardiac Electrophysiology
- National median
In program year 2025, general payments to Daniel Arzola Castaner were reported at $1,401. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.
Show as a table
| Year | Daniel Arzola Castaner | Clinical Cardiac Electrophysiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,302 | $2,361 | $585–$8,260 | $163 |
| 2020 | $1,454 | $993 | $247–$4,351 | $114 |
| 2021 | $1,025 | $1,185 | $326–$4,739 | $132 |
| 2022 | $1,203 | $2,073 | $554–$6,789 | $149 |
| 2023 | $1,744 | $2,568 | $759–$8,159 | $160 |
| 2024 | $3,291 | $2,557 | $703–$7,403 | $164 |
| 2025 | $1,401 | $2,462 | $733–$7,710 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
435
Drug cost
$115,794
Branded share of claims
39.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 113 | $76,857 | |
| Xarelto Rivaroxaban | Brand | 29 | $19,996 | |
| Multaq Dronedarone Hcl | Brand | 16 | $14,305 | |
| Metoprolol Succinate | Generic | 140 | $1,856 | |
| Flecainide Acetate | Generic | 55 | $1,532 | |
| Amiodarone Hcl | Generic | 33 | $433 | |
| Verapamil Er Verapamil Hcl | Brand | 14 | $413 | |
| Digoxin | Generic | 23 | $355 | |
| Metoprolol Tartrate | Generic | 12 | $47 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 33 billing codesPaid by Medicare
$17,553
Medicare patients
83
Services billed
318
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Diabetes | 75% | |
| High blood pressure | 75% | |
| Atrial fibrillation | 54% | |
| Heart failure | 45% | |
| Ischemic heart disease | 43% | |
| Chronic kidney disease | 43% | |
| Arthritis | 42% | |
| Cancer | 19% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
350 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Cardiac Electrophysiology in Puerto Rico
Francisco Perez
Clinical Cardiac Electrophysiology · Ponce, PR
Hector Banchs
Clinical Cardiac Electrophysiology · Carolina, PR
Hilton Franqui-Rivera
Clinical Cardiac Electrophysiology · Toa Alta, PR
Richard Silva-Cantillo
Clinical Cardiac Electrophysiology · San Juan, PR
Leonell Freytes
Clinical Cardiac Electrophysiology · Ponce, PR
Suleyka Olivero-Rivera
Clinical Cardiac Electrophysiology · Bayamon, PR
Related records
Clinical Cardiac Electrophysiology in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Cardiac Electrophysiology
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.